{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:19:14Z","timestamp":1785860354421,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The relationship between CINV duration and recurrence in subsequent cycles is largely unstudied. Our objective was to determine if patients experiencing CINV in their first cycle of chemotherapy (C1) would face increased risk of CINV in later cycles and whether the duration of the CINV would predict increased risk of recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Using data from a previously reported phase III trial, we assessed patients\u2019 recurrence of breakthrough CINV after antiemetic prophylaxis for anthracycline+cyclophosphamide (AC) for breast cancer, comparing C1 short CINV vs. extended CINV as a secondary analysis. Complete response (CR) and CINV duration were primary and secondary endpoints, respectively. CR was considered prophylaxis success; lack of CR was considered treatment failure (TF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 402 female patients, 99 (24.6%) had TF in C1 (TF1). The remaining 303 patients (CR1) had \u226593% CR rates in each subsequent cycle, while the 99 patients with TF1 had TF rates of 49.8% for cycles 2-4 (P &amp;lt; .001). The 51 patients with extended TF (\u22653 days) in C1 had recurrent TF in 73\/105 later cycles (69.5%, P &amp;lt; .001), while the 48 patients with short TF (1-2 days) in C1 had recurrent TF in 33\/108 later cycles (30.6%). The relative risk of recurrence after C1 extended TF was 2.28 (CI 1.67-3.11; P &amp;lt; .001) compared to short TF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Prophylaxis success in C1 led to &amp;gt;90% repeat success across cycles of AC-based chemotherapy. For patients with breakthrough CINV, extended duration strongly predicted recurrent CINV. The duration of CINV should be closely monitored, and augmenting antiemetic prophylaxis considered for future cycles when extended CINV occurs.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyac240","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:51:03Z","timestamp":1671295863000},"page":"208-213","source":"Crossref","is-referenced-by-count":15,"title":["Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles"],"prefix":"10.1093","volume":"28","author":[{"given":"Rudolph","family":"Navari","sequence":"first","affiliation":[{"name":"Cancer Care Program, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Binder","sequence":"additional","affiliation":[{"name":"Helsinn Therapeutics US Inc. , Iselin, NJ , USA (currently Servier Pharmaceuticals)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Molasiotis","sequence":"additional","affiliation":[{"name":"College of Arts, Humanities & Education, University of Derby , Derby , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark"},{"name":"Department of Clinical Oncology, Zealand University Hospital Roskilde , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Roeland","sequence":"additional","affiliation":[{"name":"Oregon Health and Sciences Center, Knight Cancer Institute , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D","family":"Kloth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fox Chase Cancer Center , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey A","family":"Klute","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Buffett Cancer Center , Omaha, NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-566X","authenticated-orcid":false,"given":"Eros","family":"Papademetriou","sequence":"additional","affiliation":[{"name":"SmartAnalyst, Inc. , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Schmerold","sequence":"additional","affiliation":[{"name":"SmartAnalyst, Inc. , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Renown Institute for Cancer , Reno, NV , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"4","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/onco.13620","article-title":"Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin","volume":"26","author":"Navari","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","article-title":"Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"2023041012091450700_","first-page":"676","article-title":"What the HEC?","volume":"18","author":"Roeland","year":"2020","journal-title":"Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Cancer Netw"},{"issue":"7","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023041012091450700_","author":"Centers for Medicare & Medicaid Services (CMS) H.","year":"2015"},{"issue":"156","key":"2023041012091450700_","first-page":"48772","article-title":"Medicare program: hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs; new categories for hospital outpatient department prior authorization process; clinical laboratory fee schedule: labor","volume":"85","author":"Centers for Medicare & Medicaid Services (CMS) H","year":"2020","journal-title":"Fed Regist"},{"issue":"5","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molasiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of \u00adchemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg","year":"2020","journal-title":"Oncologist"},{"key":"2023041012091450700_"},{"key":"2023041012091450700_"},{"issue":"2","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","article-title":"The impact of \u00adchemotherapy-induced nausea and vomiting on health-related quality of life","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"issue":"31_suppl","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1200\/JCO.2019.37.31_suppl.112","article-title":"Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC)","volume":"37","author":"Roeland","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"e24133","DOI":"10.1200\/JCO.2020.38.15_suppl.e24133","article-title":"Work loss and activity impairment due to duration of nausea and vomiting in \u00adpatients with breast cancer receiving CINV prophylaxis","volume":"38","author":"Schwartzberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023041012091450700_","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/208\/49806799\/oyac240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/208\/49806799\/oyac240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T01:35:29Z","timestamp":1728264929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/3\/208\/6927232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,17]]},"published-print":{"date-parts":[[2023,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac240","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,12,17]]}}}